Compare PTGX & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTGX | HLI |
|---|---|---|
| Founded | 2006 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.7B |
| IPO Year | 2016 | 2015 |
| Metric | PTGX | HLI |
|---|---|---|
| Price | $131.44 | $142.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $182.36 | $162.11 |
| AVG Volume (30 Days) | 545.9K | ★ 721.1K |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 1.95% |
| EPS Growth | N/A | ★ 6.87 |
| EPS | ★ 5.43 | 2.78 |
| Revenue | N/A | ★ $2,617,516,000.00 |
| Revenue This Year | $1,130.56 | $3.98 |
| Revenue Next Year | N/A | $14.99 |
| P/E Ratio | ★ $24.74 | $51.47 |
| Revenue Growth | N/A | ★ 9.55 |
| 52 Week Low | $77.00 | $112.83 |
| 52 Week High | $160.81 | $195.06 |
| Indicator | PTGX | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 55.18 |
| Support Level | $127.59 | $133.57 |
| Resistance Level | $143.61 | $144.28 |
| Average True Range (ATR) | 5.62 | 4.84 |
| MACD | -0.72 | -0.02 |
| Stochastic Oscillator | 16.87 | 45.80 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.